HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Deals Consumer Health Its Own Hand, Plays Waiting Game For Bids

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."

You may also be interested in...



Pfizer Plays Up Its In-house Potential, Avoids M&A Talk

Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.

P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint

P&G’s planned acquisition of Merck KGaA’s consumer health care business will grow its consumer health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories.  CEO David Taylor frames the acquisition as another step in the firm's ongoing portfolio shakeup.

GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes

Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS122714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel